More about

Thyroid Eye Disease

News
October 26, 2021
2 min read
Save

Treatment of thyroid eye disease varies between North American, European providers

Treatment of thyroid eye disease varies between North American, European providers

First-line treatment of thyroid eye disease differs around the globe, with teprotumumab the most commonly prescribed treatment in North America and IV steroids most common in Europe, according to a speaker.

News
September 20, 2021
11 min read
Save

Thyroid eye disease requires joint management with ophthalmologists

Thyroid eye disease requires joint management with ophthalmologists

Not everyone can agree on what to call thyroid eye disease. For some, it is thyroid-associated ophthalmopathy; for others, it is thyroid-related immune orbitopathy. It has also been referred to as Graves’ orbitopathy.

News
September 20, 2021
3 min read
Save

Should teprotumumab become first-line therapy for thyroid eye disease?

Should teprotumumab become first-line therapy for thyroid eye disease?

Traditionally, many experts in the field have advocated steroids. More recently, EUGOGO and others have advocated high-dose pulse steroid therapy in TED as that route of administration appears to be less associated with side effects.

News
June 24, 2021
5 min read
Save

Teprotumumab effective, safe after 1 year in clinical use

Teprotumumab effective, safe after 1 year in clinical use

Teprotumumab was approved for the treatment of thyroid eye disease in January 2020. As real-world experience with teprotumumab increases, several clinical reports describing patient responses, safety and effectiveness are now appearing.

News
June 01, 2021
12 min read
Save

Thyroid eye disease managed jointly by ophthalmologists and endocrinologists

Thyroid eye disease managed jointly by ophthalmologists and endocrinologists

Not everyone can agree on what to call thyroid eye disease.

News
June 01, 2021
2 min read
Save

Multidisciplinary management approach needed for thyroid eye disease

Multidisciplinary management approach needed for thyroid eye disease

Thyroid eye disease was first described by Robert James Graves, FRCS, an Irish surgeon who recognized the association of hyperthyroidism with exophthalmos in 1835. Even today, many use Graves’ ophthalmopathy when discussing this disease.

News
May 14, 2021
2 min watch
Save

VIDEO: Teprotumumab useful in patients with thyroid eye disease

VIDEO: Teprotumumab useful in patients with thyroid eye disease

WAILEA, Hawaii — In this video from Hawaiian Eye 2021, Roger A. Dailey, MD, discusses outcomes in patients treated for thyroid eye disease with traditional methods and teprotumumab.

News
May 08, 2021
1 min watch
Save

VIDEO: Thyroid eye disease management changed with teprotumumab approval

VIDEO: Thyroid eye disease management changed with teprotumumab approval

WAILEA, Hawaii — In this video from Hawaiian Eye, Wendy W. Lee, MD, and Roger A. Dailey, MD, discuss the latest information surrounding diagnosis and management of thyroid eye disease.

News
April 23, 2021
3 min read
Save

Teprotumumab improves short- and long-term clinical outcomes in thyroid eye disease

Teprotumumab improves short- and long-term clinical outcomes in thyroid eye disease

Most adults with thyroid eye disease receiving an infusion of teprotumumab every 3 weeks for a 24-week period had a reduction of at least 2 mm in proptosis, with a long-term response observed in 67% of participants, according to study data.

News
April 02, 2021
1 min read
Save

Horizon receives authorization to increase Tepezza production

Horizon Therapeutics has received a prior approval supplement for its previously approved biologics license application so that it can manufacture more Tepezza for the treatment of thyroid eye disease, according to a press release.

View more